| Q27011721 | CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens |
| Q37802988 | Central Nervous System Infection |
| Q30450267 | Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates |
| Q35057500 | Cognitive impairment in patients with AIDS - prevalence and severity |
| Q41522760 | Corpus callosum thickness on mid-sagittal MRI as a marker of brain volume: a pilot study in children with HIV-related brain disease and controls. |
| Q41930149 | Correlating brain volume and callosal thickness with clinical and laboratory indicators of disease severity in children with HIV-related brain disease. |
| Q36852409 | Cortical atrophy and white matter hyperintensities in HIV: the Hawaii Aging with HIV Cohort Study |
| Q24632654 | Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era |
| Q53904491 | HIV Dementia. |
| Q84127254 | Image evaluation of HIV encephalopathy: a multimodal approach using quantitative MR techniques |
| Q36072424 | Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. |
| Q39279964 | Neuroimaging in Central Nervous System Infections |
| Q95779068 | Neuroimaging of HIV-associated neurocognitive disorders |
| Q37015379 | Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. |
| Q52654834 | Scaling Synapses in the Presence of HIV. |
| Q34097562 | Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor |
| Q34129550 | White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapy |
| Q37721244 | White matter: organization and functional relevance |